While pharma has historically been hesitant to change its development and manufacturing processes lest they fall out of compliance with the industry’s strict regulatory standards, new environmental regulations, combined with emerging business incentives, are shifting the industry’s mindset. Recognizing the industry’s need to seamlessly integrate sustainability performance into R&D and production processes, new innovations seek to help pharma experts converge sustainability choices with other operational decisions.

The drugmaker shares promising interim results regarding KarXT's long-term efficacy as the drug nears its PDUFA date.

The recent approval makes Enhertu the first tumor-agnostic HER2-directed therapy.

Advanced chemical indicators give you the peace of mind that comes from reliable insights into your supply chains.

Join us each week as we do a quick review of three compelling stories you may have missed